Skip to content
10-Q

Quarterly Report

OncoMed Pharmaceuticals Inc

0001564590-18-011826

← back to feed
Filed
May 8, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2018 · May 7, 2018 38.43M sh
Capex Q1 2018 · Mar 31, 2018 $172K
Capex Q1 2018 · Mar 31, 2017 $400K
Short Term Investments Q1 2018 · Mar 31, 2018 $74.3M
Short Term Investments Q1 2018 · Dec 31, 2017 $89.81M
Cash And Equivalents Q1 2018 · Mar 31, 2018 $14.13M
Cash And Equivalents Q1 2018 · Dec 31, 2017 $13.28M
Cash And Equivalents Q1 2018 · Mar 31, 2017 $39.2M
Cash And Equivalents Q1 2018 · Dec 31, 2016 $36.95M
Stockholders Equity Q1 2018 · Mar 31, 2018 $46.33M
Stockholders Equity Q1 2018 · Dec 31, 2017 −$48.6M
Current Liabilities Q1 2018 · Mar 31, 2018 $34.87M
Current Liabilities Q1 2018 · Dec 31, 2017 $93.13M
Total Liabilities Q1 2018 · Mar 31, 2018 $48.8M
Total Liabilities Q1 2018 · Dec 31, 2017 $158.93M
Current Assets Q1 2018 · Mar 31, 2018 $90.35M
Current Assets Q1 2018 · Dec 31, 2017 $105.21M
Total Assets Q1 2018 · Mar 31, 2018 $95.13M
Total Assets Q1 2018 · Dec 31, 2017 $110.32M
Sga Expense Q1 2018 · Mar 31, 2018 $5.39M
Sga Expense Q1 2018 · Mar 31, 2017 $4.98M
Rd Expense Q1 2018 · Mar 31, 2018 $8.39M
Rd Expense Q1 2018 · Mar 31, 2017 $23.99M
Net Income Q1 2018 · Mar 31, 2018 −$5.57M
Net Income Q1 2018 · Mar 31, 2017 −$22.61M
Operating Income Q1 2018 · Mar 31, 2018 −$5.93M
Operating Income Q1 2018 · Mar 31, 2017 −$22.76M
Revenue Q1 2018 · Mar 31, 2018 $7.85M